A new study found that fecal grafting from "super-donors" could alleviate the symptoms of irritable bowel syndrome.
Researchers found that the transfer of fecal samples from these very healthy donors to IBS patients improved symptoms by more than 80 percent.  In addition, symptom remission occurred in almost half of the patients, ie no convulsions, abdominal pain, or feeling of fullness.
The Bergen University team in Norway says faecal transplants, in combination with drugs, could be used to improve the lives of IBS patients whose days are often interrupted by debilitating symptoms.
Fecal transplants have become popular in recent years, are not approved in the US and have indeed warned the Food and Drug Administration they potentially harbor the risk of serious infections.
A new study by the University of Bergen in Norway showed that 47% of IBS patients received two stool grafts According to a "super dispenser", the symptoms have completely disappeared (file image).
IBS is a bowel disease that causes abdominal pain, bloating, cramping and diarrhea or constipation.
10 to 15 percent of adults in the US experience these symptoms According to the American College of Gastroenterology, only about five to seven percent of the population was diagnosed.
The cause is unknown, but some scientists believe that they may be associated with abnormal gut bacteria.
Therefore, researchers wanted to test whether a fecal transplant, which transfers stool from a healthy donor into the gastrointestinal tract of a patient, can relieve symptoms of IBS.
The stool contains about 1,000 different bacterial species that act as probiotics and fill the digestive tract with bacteria.
According to the Cleveland Clinic, donation of the chair takes place within six hours of transplantation.
Once Doctors To determine if the sample is safe, add saline to dissolve it, and run through a coffee filter to remove particulate matter.
Transmission then takes place via an inlet, a tube inserted through the mouth or a pill containing freeze-dried material.
Some doctors say if the chair is not screened well enough, the chair could transmit a serious infection from the donor to the recipient.
For the study, the results of which were presented on Sunday at the annual United European Gastroenterology Week in London In Spain, the team recruited 164 diagnosed patients with moderate or severe symptoms.
WHAT IS A FECAL TRANSPLANTATION?
A stool transplant is the transfer of a stool from a healthy donor into the gastrointestinal tract of a patient.
It is most commonly used to treat recurrent C. difficile infections – transmitted through bacterial spores in the stool.
It can also be used to treat gastrointestinal infections such as colitis, irritable bowel syndrome and constipation.
Antibiotics often kill too many "good" bacteria in the digestive tract. Faecal transplants can help to restore bacterial balance.
The stool contains about 1,000 different bacterial species that act as probiotics.
Transmission occurs via:
- enema (fluid injected through the rectum into the lower intestine)
- Nasogastric tube (probe inserted) through the mouth, over the neck and into the stomach)
- One Pill containing lyophilized material
They were then randomly assigned either a placebo containing 30 grams of a solution containing their own feces or a solution of a so-called "super donor" of either 30 grams or 60 grams.
"We had a carefully selected multi-candidate donor with properties known to positively affect the gut microbiota," said lead author Dr. Magdy El-Salhy, Professor at the Department of Clinical Medicine, University of Bergen, told NBC News.
"Overall, the donor was healthy, breastfed, nutritious, no regular medication, nonsmokers, and only had antibiotics a few times."
The patients received the doses via a probe that went down to the mouth and throat down to the small intestine.
Researchers asked patients about their symptoms three months later. After treatment, 23.6 percent of placebo patients reported an improvement in symptoms.
In the group of super-donors 76.9 percent who received 30 grams felt an improvement, as did 89.1 percent of patients who received 60 grams.
They also found that in some cases the symptoms completely disappeared in 35.2 percent of the 30-gram superspirer group and 47.3 percent of the 60-gram group.
Only 5.5 percent of placebo treated individuals reported having no symptoms.
Dr. El-Salhy told NBC News that the impact is still felt after a year.
"Preliminary results [suggest] are still good in 90 to 95 percent of the targeted patients and still well cured in about 50 percent," he said.